Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06289075
Other study ID # 23-1096-retro
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 1, 2024
Est. completion date December 1, 2024

Study information

Verified date February 2024
Source University Hospital of Cologne
Contact Sandra Emily Stoll, DR. AP
Phone +491735697566
Email sandraemilystoll@googlemail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Objective of our retrospective multicenter- study is to forecast ICU length of stay (ICULOS) and length of mechanical ventilation (LOMV) in ICU patients of different groups (regarding gender, age group, medical vs surgical admission) worldwide for the next years up to the year of 2040 using statistical forecasting models and historical, national and international ICU databases and population databases.


Description:

Adequate resource allocation in Intensive Care Medicine is especially challenging due to limited resources and increasing demands for ICU capacities due to an aging population and medical advances. Several studies in the past were trying to predict ICULOS using different models. The Objective and aim of our retrospective multicenter study are to forecast ICU length of stay (ICULOS) and length of mechanical ventilation (LOMV) in ICU patients of different groups (regarding gender, age group, medical vs surgical admission) worldwide for the next years up to the year of 2040 using statistical forecasting models. To achieve this objective, we collect historical ICU data spanning from 2005 to 2023 from international ICU databases worldwide as well as population data from national and international databases and employ different statistical forecasting models (ARIMA-Model (Auto-Regressive Integrated Moving Average), logistic regression, Poisson Regression and ETS (Exponential smoothing)) to make these predictions. The Validity of the 4 different models is assessed with out-of-time-cross validity by splitting the data in 2 subsets for generation and testing of the model in a ratio of approximately 75:25 of the dataset. The most valid model of the 4 different models will be chosen. The statistical analysis follows he guidelines for Accurate and Transparent Health Estimates Reporting (GATHER Statement) von Stevens et al. from the year 2016. The ultimate goal of this project is to provide valuable insights to healthcare system decision-makers worldwide regarding future requirements of ICU beds and ventilator capacities. With this insight we want to enable healthcare- system decision makers worldwide to proactively anticipate and allocate appropriate ICU resources for the future.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10000000
Est. completion date December 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 1 Day to 120 Years
Eligibility Inclusion Criteria: - All patients admitted to an ICU between the years 2005-2023 Exclusion Criteria: - Patients without ICU admission or ICU admission < 4 hours

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Intensive Care Unit (ICU) treatment
ICU treatment

Locations

Country Name City State
n/a

Sponsors (6)

Lead Sponsor Collaborator
University Hospital of Cologne Albert Einstein College of Medicine, Johann Wolfgang Goethe University Hospital, Monash University, Montefiore Hospital, The Alfred

Outcome

Type Measure Description Time frame Safety issue
Primary Length of mechanical ventilation Forecasting mechanical ventilation for the next 16 years 2005-2040
Primary Length of ICU stay Forecasting ICU stay for the next 16 years 2005-2040
See also
  Status Clinical Trial Phase
Completed NCT03153397 - Effect of Prebiotic Fiber- Enriched (scFOS) Enteral Feeding on the Microbiome in Neurological Injury Trauma Patients (PreFEED Microbiome Trial) N/A
Completed NCT01116752 - Pediatric Intensive Care Units (ICUs) at Emory-Children's Center Glycemic Control: The PedETrol Trial Phase 3